CLN-978 for Sjögren's Disease
This study is testing a new treatment called CLN-978 for people with Sjögren's Disease. CLN-978 is given as a shot under the skin. The study is looking at how safe CLN-978 is and if people can tolerate it over 48 weeks. You might be able to join if you are an adult (18 or older) with Sjögren's Disease that has been active and moderate to severe for at least 24 weeks. You also need to meet specific lab requirements, including an absolute lymphocyte count (ALC) of 0 or higher. This study plans to enroll 36 participants.
- Study design
- This is a Phase 1b, open-label study, meaning both you and your doctors will know you are receiving CLN-978. It plans to enroll 36 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will follow participants for safety and tolerability for 48 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
At a glance
Conditions
Where it's being run
14 sites across 8 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Tolerability48 weeks
Incidence and severity of adverse events (AEs), serious AEs (SAEs), AEs of special interest (AESIs).